National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 84611 [2024-24542]
Download as PDF
<![CDATA[
84611
Federal Register / Vol. 89, No. 205 / Wednesday, October 23, 2024 / Notices
Tixocortol Pivala:~g
Potentially repurpoJ~d
forSARS-Co
OH
e 0
H
HOH
O
S-S ~ O
.C HI
l H
.
-'"+~
Tixocortol Pivalate
Prodrug
Dated: October 18, 2024.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
khammond on DSKJM1Z7X2PROD with NOTICES
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
18:48 Oct 22, 2024
Jkt 265001
0
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Interaction between ARVs
and Hormones in HIV and Coinfections (R01
Clinical Trial Optional).
Date: November 19, 2024.
Time: 10:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G34,
Rockville, MD 20892 (Video Assisted
Meeting).
Contact Person: Vishakha Sharma, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G34, Rockville, MD
20892, 301–761–7036, vishakha.sharma@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
PO 00000
Frm 00091
Fmt 4703
Tixocortol dfsulphide
Tixocortol
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
[FR Doc. 2024–24565 Filed 10–22–24; 8:45 am]
VerDate Sep<11>2014
0
Sfmt 4703
i
I•, o
Dated: October 18, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–24542 Filed 10–22–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Transportation Security Administration
[Docket No. TSA–2018–0001]
Surface Transportation Security
Advisory Committee; Meeting
Transportation Security
Administration, Department of
Homeland Security.
ACTION: Committee management; Notice
of open Federal advisory committee
meeting.
AGENCY:
The Transportation Security
Administration (TSA) will hold a
meeting of the Surface Transportation
Security Advisory Committee (STSAC)
on November 21, 2024. Members of the
public will be able to participate
virtually via Microsoft Teams. The
SUMMARY:
E:\FR\FM\23OCN1.SGM
23OCN1
EN23OC24.006</GPH>
HS
SARS-COV•2
]]>Agencies
[Federal Register Volume 89, Number 205 (Wednesday, October 23, 2024)]
[Notices]
[Page 84611]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-24542]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; Interaction between ARVs and
Hormones in HIV and Coinfections (R01 Clinical Trial Optional).
Date: November 19, 2024.
Time: 10:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3G34,
Rockville, MD 20892 (Video Assisted Meeting).
Contact Person: Vishakha Sharma, Ph.D., Scientific Review
Officer, Scientific Review Program, Division of Extramural
Activities, National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3G34,
Rockville, MD 20892, 301-761-7036, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: October 18, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-24542 Filed 10-22-24; 8:45 am]
BILLING CODE 4140-01-P
